评论
打印
China has included 17 cancer drugs on the medical insurance list, the country's state medical insurance administration announced last Wednesday.
国家医疗保障局上周三宣布，我国已将17种抗癌药纳入医保报销目录。
The price of the 17 drugs dropped 56.7% on average compared to the average retail price. And, they have been priced lower than market prices in neighboring countries and regions, remarkably reducing the economic burden of people battling cancer in China.
与平均零售价相比，这17种药品售价的平均降幅达56.7%。而且，其价格要低于周边国家或地区的市场价格，大幅减轻国内癌症患者的经济负担。
All of them are clinically necessary, effective, and urgently needed for cancer treatment.
这些药品均为临床必需、疗效确切、需求迫切的肿瘤治疗药品。
This June, China's drug authority launched a new round of negotiations with pharmaceutical companies on the inclusion of cancer drugs for medical insurance.
今年六月，中国药监局启动了新一轮与制药公司的谈判，内容是将抗癌药物纳入医疗保险。
44 cancer drugs that were not covered in the list were reviewed during the negotiations, and 17 drugs were finally selected to be added on the list.
在谈判中再次审议了此前44种未列入清单的癌症药物，最后选定了17种药物，将其列入清单。
The move also reflects the country's support for medical innovation and stronger push for research and development of innovative drugs.
此举还体现了我国对医药创新的支持和对研发创新药的大力推动。
10 of the 17 newly-included drugs have been publicly available since last year.
新纳入医保报销目录的17种药品中有10种为2017年后上市的品种。
